1
|
Pasqualetti G, Seghieri M, Santini E, Rossi C, Vitolo E, Giannini L, Malatesta MG, Calsolaro V, Monzani F, Solini A. P2X 7 Receptor and APOE Polymorphisms and Survival from Heart Failure: A Prospective Study in Frail Patients in a Geriatric Unit. Aging Dis 2017; 8:434-441. [PMID: 28840058 PMCID: PMC5524806 DOI: 10.14336/ad.2016.1202] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Accepted: 12/02/2016] [Indexed: 11/29/2022] Open
Abstract
Heart failure (HF) is one of the most frequent cause of hospitalization in elderly and often coexists with concurrent geriatric syndromes, like cognitive disturbances; various pathophysiological mechanisms are shared by HF and cognitive decline, notably a substrate of low-grade inflammation. We investigated whether SNPs in the purinergic receptor (P2X7R) and apolipoprotein (APO) E genes, both involved in a series of inflammatory responses, are associated to HF or cognitive impairment and are able to predict post-discharge mortality in the elderly. We prospectively analyzed 198 patients (age 85 ± 8 years, predominantly females) admitted to a Geriatric unit for acute HF, whose diagnosis was based on clinical signs, brain natriuretic peptide (BNP) values and ecocardiography in uncertain diagnosis (BNP values between 100 and 400 pg/mL); cognitive performance was assesed by Short Portable Mental Status Questionnaire (SPMSQ). In all the participants, SNPs rs208294 and rs3751143 for P2X7R gene and rs429558 and rs7412 for APOE gene were assessed. Information on all-cause mortality was adjudicated by medical records review 36 months after discharge. We found no relationship between P2X7R and APOE polymorphisms and 36-month post-discharge mortality; a better outcome for overall survival was observed in patients with BNP values below the median (281 pg/mL) (p=0.002) persisting after adjustment for renal function and age, and in those with cognitive impairment (p<0.001). Patients harboring APOE-ε4 genotype showed higher BNP concentrations than noncarriers (1289.9 ± 226.9 vs 580.5 ± 90.2 pg/mL respectively,p=0.004), whereas none of the studied SNPs were associated to impairment in cognitive performance. In conclusion, neither P2X7R or APOE genotype seem to predict long-term mortality in elderly patients. Interestingly, APOE-ε4 genotype was associated to higher BNP values, suggesting a putative interaction between genetic and biochemical markers in identifying people at risk for HF.
Collapse
Affiliation(s)
- Giuseppe Pasqualetti
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| | - Marta Seghieri
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| | - Eleonora Santini
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| | - Chiara Rossi
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| | - Edoardo Vitolo
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| | - Livia Giannini
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| | | | - Valeria Calsolaro
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| | - Fabio Monzani
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| | - Anna Solini
- Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy
| |
Collapse
|
2
|
Belohlavek M, Jiamsripong P, Calleja AM, McMahon EM, Maarouf CL, Kokjohn TA, Chaffin TL, Vedders LJ, Garami Z, Beach TG, Sabbagh MN, Roher AE. Patients with Alzheimer disease have altered transmitral flow: echocardiographic analysis of the vortex formation time. JOURNAL OF ULTRASOUND IN MEDICINE : OFFICIAL JOURNAL OF THE AMERICAN INSTITUTE OF ULTRASOUND IN MEDICINE 2009; 28:1493-1500. [PMID: 19854964 DOI: 10.7863/jum.2009.28.11.1493] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
OBJECTIVE There is considerable epidemiologic evidence that Alzheimer disease (AD) is linked to cardiovascular risk factors and associated with an increased risk of symptomatic left ventricular (LV) dysfunction. Formation of a vortex alongside a diastolic jet signifies an efficient blood transport mechanism. The vortex formation time (VFT) is an index of optimal conditions for vortex formation. We hypothesized that AD and its associated cardiovascular risk factors impair diastolic transmitral flow efficiency and, therefore, shift the VFT value out of its optimal range. METHODS Echocardiographic studies were performed on 45 participants in total: 22 patients with AD diagnosed according to the American Psychiatric Association's criteria and 23 age-matched individuals as a control group with cognitive function within normal limits. RESULTS The echocardiographic ratio of the early to atrial phases of the LV filling velocities was significantly lower in the AD group (mean +/- SD, 0.67 +/- 14) when compared with the control individuals (0.79 +/- 0.14; P = .003). The interventricular septum diastolic thickness, left ventricular posterior wall diastolic thickness, and right ventricular end-diastolic diameter were significantly higher in the AD group (P <or= 0.04). The mitral annular diameters in the control and AD groups were nearly identical (P = .725). The time-velocity integral of the E wave had a lower value in the AD group than in the control group (P = .05), whereas the VFT was significantly lower in the AD group (P = .018). CONCLUSIONS Our study suggests that patients with AD have impaired transmitral flow efficiency of diastolic filling, as measured by the VFT, compared with age-matched control individuals.
Collapse
Affiliation(s)
- Marek Belohlavek
- Translational Ultrasound Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Oudshoorn C, Mattace-Raso FUS, van der Velde N, Colin EM, van der Cammen TJM. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2008; 25:539-43. [PMID: 18503256 DOI: 10.1159/000134382] [Citation(s) in RCA: 115] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/08/2008] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND/AIMS Recent studies suggest that vitamin D metabolites may be important for preserving cognitive function via specific neuroprotective effects. No large studies have examined the association between vitamin D status and cognition. METHODS In this cross-sectional study, we analyzed the serum 25-hydroxyvitamin D(3) levels and Mini-Mental State Examination (MMSE) test scores of 225 older outpatients who were diagnosed as having probable Alzheimer's disease (AD). In addition to the 25-hydroxyvitamin D(3) levels, we analyzed the serum vitamin B(1), B(6) and B(12) levels. RESULTS An association was found between MMSE test scores and serum 25-hydroxyvitamin D(3) levels, with a beta-coefficient of 0.05 (p = 0.01). Vitamin-D-sufficient patients had significantly higher MMSE scores as compared to vitamin-D-insufficient ones. No association was found with the other serum vitamin levels. CONCLUSIONS These data support the idea that a relationship exists between vitamin D status and cognition in patients with probable AD. However, given the cross-sectional design of this study, no causality can be concluded. Further prospective studies are needed to specify the contribution of vitamin D status to the onset and course of cognitive decline and AD.
Collapse
Affiliation(s)
- C Oudshoorn
- Department of Internal Medicine, Section of Geriatric Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
| | | | | | | | | |
Collapse
|
4
|
Reitz C, Brickman AM, Luchsinger JA, Wu WE, Small SA, Tang MX, Mayeux R. Frequency of subclinical heart disease in elderly persons with dementia. ACTA ACUST UNITED AC 2007; 16:183-8. [PMID: 17483671 PMCID: PMC2669795 DOI: 10.1111/j.1076-7460.2007.06511.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The authors compared the frequency of structural and functional heart abnormalities assessed using transthoracic echocardiography among persons with Alzheimer's disease, vascular dementia, stroke, and healthy control subjects. Compared with controls, patients with Alzheimer's disease were more likely to have aortic valve thickening, aortic valve regurgitation, left ventricular wall motion abnormalities, left ventricular hypertrophy, and reduced ejection fraction. Persons with vascular dementia were more likely to have aortic valve regurgitation, but mitral valve thickening and tricuspid valve regurgitation were also more frequent. In the absence of dementia, persons with stroke differed from controls by more frequent mitral valve calcifications. With the increasing prevalence of Alzheimer's disease and vascular dementia, clinicians have to be more attentive to the presence of structural heart disease and its complications in persons with these conditions.
Collapse
Affiliation(s)
- Christiane Reitz
- The Gertrude H. Sergievsky Center (Reitz, Luchsinger, Small, Tang, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - Adam M. Brickman
- The Taub Institute for Research on Alzheimer's Disease and the Aging Brain (Brickman, Wu, Small, Luchsinger, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - José A. Luchsinger
- The Gertrude H. Sergievsky Center (Reitz, Luchsinger, Small, Tang, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
- The Taub Institute for Research on Alzheimer's Disease and the Aging Brain (Brickman, Wu, Small, Luchsinger, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
- The Department of Medicine (Luchsinger) Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - William E. Wu
- The Taub Institute for Research on Alzheimer's Disease and the Aging Brain (Brickman, Wu, Small, Luchsinger, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - Scott A. Small
- The Gertrude H. Sergievsky Center (Reitz, Luchsinger, Small, Tang, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
- The Taub Institute for Research on Alzheimer's Disease and the Aging Brain (Brickman, Wu, Small, Luchsinger, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
- The Department of Neurology (Small and Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - Ming-Xin Tang
- The Gertrude H. Sergievsky Center (Reitz, Luchsinger, Small, Tang, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
- The Department of Biostatistics in the Mailman School of Public Health (Tang) Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - Richard Mayeux
- The Gertrude H. Sergievsky Center (Reitz, Luchsinger, Small, Tang, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
- The Taub Institute for Research on Alzheimer's Disease and the Aging Brain (Brickman, Wu, Small, Luchsinger, Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
- The Department of Neurology (Small and Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
- The Department of Psychiatry (Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
- The Department of Epidemiology in the Mailman School of Public Health (Mayeux) Columbia University College of Physicians and Surgeons, New York, NY, USA
| |
Collapse
|
5
|
Bleumink GS, van Duijn CM, Kingma JH, Witteman JCM, Hofman A, Stricker BHC. Apolipoprotein E epsilon4 allele is associated with left ventricular systolic dysfunction. Am Heart J 2004; 147:685-9. [PMID: 15077085 DOI: 10.1016/j.ahj.2003.11.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Apolipoprotein (APOE) epsilon4 allele has been associated with cardiac dysfunction in Alzheimer's disease and beta-thalassemia. We investigated the association between APOE genotypes and left ventricular dysfunction in a population of community-dwelling elderly subjects. METHODS This study was performed in the Rotterdam Study, a population-based prospective cohort study among elderly subjects. For 2206 participants, a baseline echocardiogram and blood specimens for APOE typing were available. Cardiac dysfunction was considered present when fractional shortening was <or=25%. Multivariate logistic regression was used to calculate odds ratios (ORs). The epsilon3/epsilon3 genotype served as a reference category. RESULTS In participants who were homozygous for the epsilon4 allele, the odds of cardiac dysfunction was increased 3-fold (OR, 3.1; 95% CI, 1.2-8.1), whereas the odds of cardiac dysfunction in persons with APOE epsilon3/epsilon4 was not significantly increased (OR, 1.5; 95% CI, 0.9-2.5). There was a significant allele-effect relationship for the epsilon4 allele (P-trend <.05). These elevated odds remained after adjustment for cholesterol levels and atherosclerosis parameters. Risks associated with APOE epsilon4/epsilon4 and APOE epsilon3/epsilon4 were more pronounced in participants aged >or=65 years. CONCLUSION The APOE epsilon4 allele is an independent risk factor for cardiac dysfunction in elderly people. Besides well-known effects on atherosclerosis and cholesterol levels, there may be other mechanisms, such as apoptosis, through which this allele exerts negative effects on myocardial performance.
Collapse
Affiliation(s)
- Gysèle S Bleumink
- Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
6
|
Abstract
Alzheimer's disease (AD) and vascular dementia (VaD) are the two most common forms of dementia. In Europe, 800,000 people have a diagnosis of VaD out of 3.7 million people with clinical dementia. These two dementia types share many common pathological, symptomatic and neurochemical features, and cholinergic treatments that have demonstrated robust, broad-ranging and long-term efficacy in AD are now being assessed for the treatment of dementia related to cerebrovascular disease (CVD). There has been recent recognition that dementia in the elderly is a continuum of pathologies, with pure AD and VaD representing the two extremes, and 'mixed' dementia (AD with CVD) in between and perhaps comprising the majority of cases. 'Mixed' dementia is rarely diagnosed in the clinic, however, as the majority of diagnostic procedures are biased toward a diagnosis of AD. Here, the risk factors, pathophysiological mechanisms and clinical symptoms of AD and VaD are described, identifying their overlap as well as some of the differences in both cognitive and noncognitive symptoms. Important findings indicating the high prevalence of 'mixed' dementia in the clinical dementia population are also discussed. In particular, evidence of a causal connection between stroke or CVD and AD is addressed. Regarding effective therapeutic management of dementia patients, further concerted epidemiological study of these related dementia types should aid in clinical decisions on the applicability of cholinergic treatments.
Collapse
Affiliation(s)
- Raj Kalaria
- Institute for Ageing and Health, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK.
| |
Collapse
|
7
|
Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2002; 57:M173-7. [PMID: 11867654 DOI: 10.1093/gerona/57.3.m173] [Citation(s) in RCA: 169] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We examined the prevalence of comorbid medical illnesses in Alzheimer's disease (AD) patients at different severity levels. We also examined the effect of cumulative medical comorbidity on cognition and function. METHODS Analyses of data from 679 AD patients (Mini-Mental State Exam score range 0-30, mean +/- SD = 11.8 +/- 8) from 13 sites (four dementia centers assessing outpatients, four managed care organizations, two assisted living facilities, and three nursing homes) prospectively recruited using a stratification approach including dementia severity and care setting. Medical comorbidity was quantified using the Cumulative Illness Rating Scale-Geriatric. RESULTS Across patients, 61% had three or more comorbid medical illnesses. Adjusting for age, gender, race, and care setting, medical comorbidity increased with dementia severity (mild to moderate, p <.01; moderate to severe, p <.001). Adjusting for age, educational level, gender, race, and care setting, higher medical comorbidity was associated with greater impairment in cognition (p <.001) and in self-care (p <.001). CONCLUSIONS Despite the limitation of a cross-sectional design, our initial findings suggest that there is a strong association between medical comorbidity and cognitive status in AD. Optimal management of medical illnesses may offer potential to improve cognition in AD.
Collapse
Affiliation(s)
- P Murali Doraiswamy
- Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA.
| | | | | | | | | |
Collapse
|
8
|
Abstract
Progress in molecular genetics has enabled the dissection of several autosomal dominantly inherited forms of cerebrovascular disorders. Mutations in diverse genes might induce pathological changes in intracranial vessels, resulting in cerebral haemorrhages and ischaemic strokes. Such pathologies, however, might also result from systemic vascular disease caused by mutations or polymorphisms in genes that regulate cardiovascular physiology, blood coagulation, lipid metabolism and metabolic functions. Interestingly, several mutations that directly affect CNS vasculature involve genes that control inter- or intracellular signalling functions. Although highly variable phenotypes make it difficult to pinpoint the genotypes, genetic characterization of cerebrovascular disorders is valuable for understanding the pathogenesis and management of sporadic disease.
Collapse
Affiliation(s)
- R N Kalaria
- Wolfson Research Centre, Institute for Health of the Elderly, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, UK
| |
Collapse
|
9
|
Abstract
Several studies confirm cognitive impairment and dementia to be increased after stroke in the elderly. Although not necessarily involving memory deficits, the frequency of cognitive impairments may occur in up to 30% of stroke survivors at 3 months. This impairment may be confounded by preexisting cognitive decline or dementia. By contrast, cognitive changes and dementia are widely recognized in familial forms of stroke, such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Several factors, including type of stroke, recurrent episodes, the site and laterality of the lesion(s), volume of cerebral infarction, medial temporal lobe atrophy, and coexistent neurodegenerative pathology predict the degree of impairment. Aphasia, diabetes mellitus, atrial fibrillation, and depression are listed among other biologic factors that further exacerbate cognition and affect long-term survival. There is no clear consensus whether genetic factors, such as the apolipoprotein E e4 allele or angiotensin converting enzyme gene polymorphisms, modify cognitive changes or stroke outcome. Although several neurotransmitter systems may be affected in post-stroke dementia, the amelioration of cholinergic function is a worthy target.
Collapse
Affiliation(s)
- R N Kalaria
- CBV Group, Wolfson Research Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, United Kingdom.
| | | |
Collapse
|
10
|
Polidori MC, Marvardi M, Cherubini A, Senin U, Mecocci P. Heart disease and vascular risk factors in the cognitively impaired elderly: implications for Alzheimer's dementia. AGING (MILAN, ITALY) 2001; 13:231-9. [PMID: 11442305 DOI: 10.1007/bf03351481] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The term "cardiogenic dementia" was introduced a few decades ago to indicate an alteration of consciousness and cognition due to heart disease. Although this term is now disused, the relationship between cardiovascular disease and cognitive impairment is currently of great interest, not only for its potential therapeutic implications. but also for the recently recognized important role that vascular factors appear to play in Alzheimer's disease. The aims of this review are therefore 1) to show data supporting the role of cardiac disease--namely congestive heart failure, myocardial infarction and atrial fibrillation--and other vascular risk factors--i.e., hypertension and diabetes--in the development or worsening of cognitive impairment; 2) to highlight recent observations on the relationship between presence and severity of congestive heart failure/ myocardial infarction/atrial fibrillation and Alzheimer's disease: and 3) to uncover the type of studies needed in this field in order to facilitate a more precise algorithm of dementia prevention as well as intervention in demented patients with cardiovascular disease.
Collapse
Affiliation(s)
- M C Polidori
- Institute of Physiological Chemistry I, Heinrich-Heine University, Düsseldorf, Germany.
| | | | | | | | | |
Collapse
|
11
|
Harrington F, Saxby BK, McKeith IG, Wesnes K, Ford GA. Cognitive performance in hypertensive and normotensive older subjects. Hypertension 2000; 36:1079-82. [PMID: 11116128 DOI: 10.1161/01.hyp.36.6.1079] [Citation(s) in RCA: 129] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Longitudinal studies suggest that hypertension in midlife is associated with cognitive impairment in later life. Cross-sectional studies are difficult to interpret because blood pressure can change with onset of dementia and the inclusion of subjects on treatment and with hypertensive end-organ damage can make analysis difficult. We examined cognitive performance in hypertensive and normotensive subjects without dementia or stroke >/=70 years of age. Cognitive performance was determined with the use of a computerized assessment battery in 107 untreated hypertensives (55 women, age 76+/-4 years, blood pressure, 164+/-9/89+/-7; range, 138 to 179/68 to 99 mm Hg) and 116 normotensives (51 female, age 76+/-4 years, 131+/-10/74+/-7; 108 to 149/60 to 89 mm Hg). Older subjects with hypertension were significantly slower in all tests (reaction time, milliseconds; simple, 346+/-100 versus 318+/-56, P<0.05; memory scanning, 867+/-243 versus 789+/-159, P<0.01; immediate word recognition, 947+/-261 versus 886+/-192, P<0.05; and delayed word recognition, 937+/-230 versus 856+/-184, P<0.05; picture recognition, 952+/-184 versus 894+/-137, P<0.01; spatial memory, 1390+/-439 versus 1258+/-394, P<0.01; excepting choice reaction time, 510+/-75 versus 498+/-72, P=0.08). Accuracy was also impaired in tests of number vigilance, 99.2+/-2.5% versus 99.9+/-0.9, P<0.01; delayed word recognition, 83.5+/-16 versus 87.9+/-9.8, P<0.01; and spatial memory 64+/-32 versus 79+/-20, P<0.001. Hypertension in older subjects is associated with impaired cognition in a broad range of areas in the absence of clinically evident target organ damage.
Collapse
Affiliation(s)
- F Harrington
- Institute for the Health of the Elderly, University of Newcastle Upon Tyne, UK
| | | | | | | | | |
Collapse
|
12
|
Abstract
OBJECTIVE The low incidence of schizophrenia prohibits large scale prevention trials, and the question arises whether such studies become more feasible by taking into account genetic factors. The aim of the paper was to inform preventive endeavours with an account of the genetic background to schizophrenia. METHOD The family, twin and adoptive studies of schizophrenia are reviewed and recent molecular genetic data presented. RESULTS Children of a parent diagnosed with schizophrenia have a ten-fold increased risk of developing the disorder. Twin and adoption studies strongly suggest the risk increase is mainly due to genetic factors. On an individual level, a positive family history is the strongest known risk factor for schizophrenia. For a prevention study, very large numbers of families have to be screened in order to reach a sufficient sample size. CONCLUSIONS One obvious way to increase the accuracy of predicting who is at high risk of developing schizophrenia would be to find specific mutations in the human genome. Attempts to isolate specific genes by means of linkage and association studies have been unsuccessful so far and, given the number of genes involved, it is extremely unlikely that the predictive value of individual genes will be high enough to warrant intervention. Genetic studies also suggest the genetic liability extends beyond the traditional clinical phenotypes. Prevention trials might become possible by adopting a broader approach.
Collapse
Affiliation(s)
- J Hallmayer
- University of Western Australia/Graylands Hospital Centre for Clinical Research in Neuropsychiatry, Perth, Australia.
| |
Collapse
|
13
|
Slagboom PE, Heijmans BT, Beekman M, Westendorp RG, Meulenbelt I. Genetics of human aging. The search for genes contributing to human longevity and diseases of the old. Ann N Y Acad Sci 2000; 908:50-63. [PMID: 10911947 DOI: 10.1111/j.1749-6632.2000.tb06635.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
An aging population of humans reflects early-onset morbidity and mortality as well as late-onset disease in the phase when the mortality rate doubles and, finally, longevity of extremely long-lived subjects. Genetic influences have been reported to be relevant for each of these three phases. A growing field in genetic research is aimed at the identification of genes involved in multifactorial diseases of the old and in longevity. Important issues in these studies include the definition of phenotype, which maximally highlights the genetic contribution, whether earlier and later onset phenotypes have loci in common, and how to rank or reject the many candidate disease loci found in different studies. These issues will be illustrated from research on cardiovascular disease and osteoarthritis.
Collapse
Affiliation(s)
- P E Slagboom
- Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands.
| | | | | | | | | |
Collapse
|
14
|
Abstract
The Alzheimer type of dementia and stroke are known to increase at comparable rates with age. Recent advances suggest that vascular risk factors linked to cerebrovascular disease and stroke in the elderly significantly increase the risk of developing Alzheimer's disease (AD). These include atherosclerosis, atrial fibrillation, coronary artery disease, hypertension, and diabetes mellitus. Moreover, review of various autopsy series shows that 60-90% of AD cases exhibit variable cerebrovascular pathology. Although some vascular lesions such as cerebral amyloid angiopathy, endothelial degeneration, and periventricular white matter lesions are evident in most cases of AD, a third will exhibit cerebral infarction. Despite the interpretation of pathological evidence, longitudinal clinical studies suggest that the co-existence of stroke and AD occurs more than by chance alone. Strokes known to occur in patients with Alzheimer syndrome and most frequently in the oldest old substantially worsen cognitive decline and outcome, implicating some interaction between the disorders. Nevertheless, the nature of a true relationship between the two disorders seems little explored. What predisposes to strokes in underlying cognitive decline or AD? Is it possible that cerebral ischemia is a causal factor for AD? I examined several vascular factors and the vascular pathophysiology implicated in stroke and AD, and propose that cerebral ischemia or oligemia may promote Alzheimer type of changes in the aging brain. Irrespective of the ultimate pathogenetic mechanism, these approaches implicate that management of peripheral vascular disease is important in the treatment or prevention of Alzheimer's disease or mixed dementia.
Collapse
Affiliation(s)
- R N Kalaria
- Wolfson Research Centre, Institute for Health of the Elderly, Newcastle General Hospital, Westgate Road, NE4 6BE, Newcastle upon Tyne, United Kingdom.
| |
Collapse
|
15
|
de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 2000; 21:331-42. [PMID: 10867218 DOI: 10.1016/s0197-4580(00)00111-1] [Citation(s) in RCA: 209] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
This review discusses the experimental and clinical data which indicate that chronic cerebral hypoperfusion can affect metabolic, anatomic, and cognitive function adversely. In aged but not young animals, chronic brain hypoperfusion results in regional pre- and post-synaptic changes, protein synthesis abnormalities, energy metabolic dysregulation, reduced glucose utilization, cholinergic receptor loss, and visuo-spatial memory deficits. Additionally, aging animals that are kept for prolonged periods of time after chronic brain hypoperfusion, also develop brain capillary degeneration in CA1 hippocampus and neuronal damage extending from the hippocampal region to the temporo-parietal cortex where neurodegenerative tissue atrophy eventually forms. All these pathologic events occur in rodents in the absence of senile plaques and neurofibrillary tangles. Alzheimer brains reveal similar biochemical and structural changes as those experimentally induced in aging animals. Moreover, regional cerebral hypoperfusion is one of the earlier (if not the earliest) clinical manifestations in both the sporadic and familial forms of Alzheimer's disease. In addition, therapy that improves or increases cerebral perfusion is generally of some benefit to Alzheimer patients. Conversely, a variety of disorders with different etiologies that impair or diminish cerebral perfusion are reported to be risk factors for this dementia. These findings have prompted us to propose the concept that advanced aging in the presence of a vascular risk factor can converge to create a critically attained threshold of cerebral hypoperfusion (CATCH) that triggers regional brain microcirculatory disturbances and impairs optimal delivery of energy substrates needed for normal brain cell function. The outcome of this defect generates a chain of events leading to the progressive evolution of brain metabolic, cognitive and tissue pathology that characterize Alzheimer's disease. The possible role of CATCH in familial and early onset Alzheimer's disease is briefly discussed from a theoretical vantagepoint. The growing and most recent evidence in support of the CATCH concept is the focus of this review.
Collapse
Affiliation(s)
- J C de la Torre
- Department of Neurosciences (MTF-0624), University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0624, USA.
| |
Collapse
|